mek162
Showing 1 - 19 of 19
Gastrointestinal Stromal Tumor (GIST) Trial in New York (drug, other, procedure)
Active, not recruiting
- Gastrointestinal Stromal Tumor (GIST)
- MEK162
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 28, 2022
Low-Grade Gliomas, Malignant Tumors, Brain, Soft Tissue Tumors Trial in United States (MEK162)
Active, not recruiting
- Low-Grade Gliomas
- +2 more
- MEK162
-
Birmingham, Alabama
- +14 more
Jan 25, 2023
Solid Tumors Harboring a BRAF V600 Mutation Trial in Worldwide (LGX818, MEK162, LEE011)
Active, not recruiting
- Solid Tumors Harboring a BRAF V600 Mutation
- LGX818
- +2 more
-
Tampa, Florida
- +22 more
Mar 16, 2022
Gastrointestinal Stromal Tumor (GIST) Trial in New York (MEK162, Pexidartinib)
Completed
- Gastrointestinal Stromal Tumor (GIST)
- MEK162
- Pexidartinib
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 29, 2021
BRAF or NRAS Mutant Metastatic Melanoma Trial in Worldwide (MEK162)
Active, not recruiting
- BRAF or NRAS Mutant Metastatic Melanoma
- MEK162
-
Fayetteville, Arkansas
- +20 more
Nov 18, 2021
Advanced Biliary Tract Carcinoma Trial in New York (Gemcitabine, Cisplatin, MEK162)
Completed
- Advanced Biliary Tract Carcinoma
- Gemcitabine
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 26, 2020
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma Trial in Guangzhou (BYL719, INC280, LDK378)
Completed
- Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
- BYL719
- +3 more
-
Guangzhou, Guangdong, ChinaNovartis Investigative Site
Nov 20, 2020
Metastatic Colorectal Cancer Trial in Worldwide (MEK162, Panitumumab)
Completed
- Metastatic Colorectal Cancer
- MEK162
- Panitumumab
-
Los Angeles, California
- +7 more
Jan 27, 2021
Advanced Solid Tumor Trial in Nagoya-city, Yufu (MEK162)
Completed
- Advanced Solid Tumor
- MEK162
-
Nagoya-city, Aichi, Japan
- +1 more
Sep 30, 2020
Cardiomegaly Trial in Boston, London (MEK162)
Withdrawn
- Cardiomegaly
- MEK162
-
Boston, Massachusetts
- +1 more
Oct 2, 2020
Metastatic Melanoma Trial in Worldwide (LGX818, MEK162, Nivolumab)
Active, not recruiting
- Metastatic Melanoma
- LGX818
- +3 more
-
Salzburg, AT, Austria
- +29 more
Feb 23, 2022
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma Trial in Worldwide (MEK162, AMG 479)
Terminated
- Metastatic Pancreatic Adenocarcinoma
- BRAF Mutated Melanoma
- MEK162
- AMG 479
-
Boston, Massachusetts
- +8 more
Dec 9, 2020
Hepatic Impairment Trial in United States (MEK162)
Terminated
- Hepatic Impairment
- MEK162
-
Lakewood, Colorado
- +4 more
Sep 16, 2020
Locally Advanced or Metastatic NRAS Mutant Melanoma Trial in Worldwide (LEE011, MEK162)
Completed
- Locally Advanced or Metastatic NRAS Mutant Melanoma
- LEE011
- MEK162
-
San Francisco, California
- +16 more
Nov 23, 2020
Solid Tumor and Hematologic Malignancies Trial in United States (MEK162)
Completed
- Solid Tumor and Hematologic Malignancies
- MEK162
-
Mobile, Alabama
- +67 more
Feb 2, 2021
Metastatic or Unresectable Cutaneous Melanoma Trial in Worldwide (MEK162, Dacarbazine)
Completed
- Metastatic or Unresectable Cutaneous Melanoma
- MEK162
- Dacarbazine
-
Fayetteville, Arkansas
- +228 more
Mar 18, 2021
Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS Trial in Worldwide (BYL719, MEK162)
Completed
- Advanced and Selected Solid Tumors
- +2 more
- BYL719
- MEK162
-
La Jolla, California
- +15 more
Sep 29, 2017